Divalproex Sodium
Product Images NDC 55648-973

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55648-973). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label (Divalproex Dr Tablets Container Labels 125 mg 100 Tab)

The label for Divalproex Sodium Delayed-Release Tablets, USP, 125 mg, manufactured by Wockhardt Limited. The label includes strength (125 mg), active ingredient mention (valproic acid activity), quantity (100 tablets), a barcode, and standard dispensing instructions noting it is for prescription use only and to dispense with the patient information sheet.*

FDA Label Image

Bottle Label (Divalproex Dr Tablets Container Labels 250 mg 500 Tab)

Label for Divalproex Sodium Delayed-Release Tablets, USP 250 mg, manufactured by Wockhardt Limited. The label indicates the product contains 500 tablets with valproic acid activity and includes storage and dispensing instructions. The label also features the NDC 64679-974-02 and a barcode.*

FDA Label Image

Bottle Label (Divalproex Dr Tablets Container Labels 500 mg 500 Tab)

Label for Divalproex Sodium Delayed-Release Tablets, USP 500 mg by Wockhardt Limited. The label states each tablet contains valproic acid activity equivalent to 500 mg Divalproex sodium, with 500 tablets per container. It includes instructions to dispense with a patient information sheet and notes the product is prescription only. The label also features a barcode and packaging details.*

FDA Label Image

Figure1 (Figure1)

A bar chart comparing the percentages of two groups, PBO and DVPX, in two separate studies labeled Study 1 (YMRS) and Study 2 (MRS). The DVPX group shows higher percentages (60% and 58%) compared to the PBO group (26% and 29%) in both studies.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing two studies measuring a variable with placebo and Divalproex sodium delayed-release tablets. Each study shows higher values for the placebo group and lower values for the Divalproex sodium delayed-release tablets group.*

FDA Label Image

Figure3 (Figure3)

A cumulative response curve comparing the percent reduction in CPS rate for patients taking Divalproex Sodium delayed-release tablets versus placebo. The y-axis shows percent reduction in CPS rate from -100% to 100%, and the x-axis shows the percent of patients from 0 to 100%. The chart illustrates improvement versus worsening over the course of the study.*

FDA Label Image

Figure4 (Figure4)

A cumulative percentage graph showing the % reduction in CPS (complex partial seizures) rate in patients treated with DIVALPROEX SODIUM. The x-axis represents the percentage of patients, decreasing from 100% to 0%, and the y-axis shows the percentage reduction in CPS rate from -100% to 100%. Two curves are depicted: a solid line for high dose and a dashed line for low dose, indicating patient improvement, no change, or worsening.*

FDA Label Image

Strecture (Structure01)

Chemical structure of divalproex sodium displaying the molecular arrangement of its components, including the sodium ion and the valproate groups as depicted in the formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.